465 related articles for article (PubMed ID: 27566699)
1. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
5. Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff R; van Giessen A; Pouwels X; Fayter D; Lang S; Armstrong N; Worthy G; Duffy S; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Mar; 36(3):285-288. PubMed ID: 29177842
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
7. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
8. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Wolff R; Ramaekers BLT; Van Giessen A; Lang S; Ryder S; Worthy G; Duffy S; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 May; 36(5):533-543. PubMed ID: 29344794
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
13. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Petersohn S; Carrera VH; Denniston AK; Chalker A; Raatz H; Armstrong N; Shah D; Witlox W; Worthy G; Noake C; Riemsma R; Kleijnen J; Joore MA
Pharmacoeconomics; 2020 May; 38(5):431-441. PubMed ID: 31701471
[TBL] [Abstract][Full Text] [Related]
14. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox W; Grimm S; Howick J; Armstrong N; Ahmadu C; McDermott K; Otten T; Noake C; Wolff R; Joore M
Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
16. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Otten T; Riemsma R; Wijnen B; Armstrong N; Stirk L; Gordon C; Ramaekers B; Kleijnen J; Joore M; Grimm S
Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
18. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox WJA; Grimm SE; Riemsma R; Armstrong N; Ryder S; Duffy S; Carrera VH; Posadzki P; Worthy G; Pouwels XGLV; Ramaekers BLT; Kleijnen J; Joore MA; van Asselt ADI
Pharmacoeconomics; 2021 Feb; 39(2):171-180. PubMed ID: 33145711
[TBL] [Abstract][Full Text] [Related]
20. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]